Application
A. Western blot analysis of anti-RelB RabMAb (Cat. #AJ1685a), dilution 1:500. A: Raji B: DaudiApplication
B. Immunohistochemical analysis of paraffin-embedded human lymphoma using anti-ReIB RabMAb (Cat. #AJ1685a).| Product Name | RelB Antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | RELB, Transcription factor RelB |
| Clonality | Monoclonal |
|---|---|
| Clone Number | EP613Y |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | RELB Transcription factor RelB |
|---|---|
| Molecular Weight(MW) | 62134 Da |
| Function | NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment |
| Tissue Specificity | A synthetic peptide corresponding to residues in near the N-term of human RelB was used as immunogen. |
| Cellular Localization | Nucleus. Cytoplasm, cytoskeleton, centrosome. Note=Co-localizes with NEK6 in the centrosome |
| Entrez Gene | 5971 |
|---|
Application
A. Western blot analysis of anti-RelB RabMAb (Cat. #AJ1685a), dilution 1:500. A: Raji B: Daudi
Application
B. Immunohistochemical analysis of paraffin-embedded human lymphoma using anti-ReIB RabMAb (Cat. #AJ1685a).| Application Notes | WB:1:500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
